ALDAVER Raises $8.4M to Expand Biopolymer-Based Artificial Organ Simulators


‘ALDAVER,’ a Korean startup developing next-generation medical simulators using advanced biopolymer materials, has raised $8.4 million (KRW 11 billion) in Series A funding. New investors SL Investment, Korea Investment Partners, and DAYLI Partners participated in this round, along with follow-up investments from existing backers KB Investment and Ascendo Ventures.

ALDAVER specializes in creating artificial organs for medical devices and training simulators using biopolymer synthesis and 3D printing technology. Testing at 10 training centers across six countries, in collaboration with global medical device companies, has shown that ALDAVER’s artificial organs replicate the mechanical and electrical properties of real organs. Medical professionals have confirmed their potential as an alternative to live pigs currently used in simulations.

The demand for biological simulators, such as pigs and cadavers, has grown due to advancements in medical technologies like surgical robots. However, ethical and legal restrictions have created supply challenges, increasing the need for next-generation simulators. With this funding, ALDAVER plans to expand its artificial organ simulator business from urology to laparoscopy and accelerate its global market entry by recruiting experienced global marketing talent.

Kim Jin-oh, co-CEO of ALDAVER, stated, “This investment will enable us to fully operate our artificial organ manufacturing facility, which was completed in the Osong High-Tech Medical Complex in October. We aim to ensure product quality and start proof-of-concept (PoC) testing with global medical device companies next year. Our mid- to long-term goal is to develop simulators for all human organs and establish ALDAVER as a global medical simulator leader through new material innovation.”

An investment analyst explained the rationale for the funding: “ALDAVER combines deep expertise in biopolymers with cutting-edge technology to deliver surgical simulations that closely mimic real conditions. Despite being a young company, it has already attracted significant interest and development requests from global medical device companies. Their ongoing research, aimed at replicating not just structure and texture but also blood flow and fine muscle movements, demonstrates high growth potential.”

Share

Leave a Reply

Your email address will not be published. Required fields are marked *